Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel γ-Secretase Modulator, Reduces Brain β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity

Bruno P. Imbimbo, Elda Del Giudice, Davide Colavito, Antonello D'Arrigo, Maurizio Dalle Carbonare, Gino Villetti, Fabrizio Facchinetti, Roberta Volta, Vladimiro Pietrini, Maria F. Baroc, Lutgarde Serneels, Bart De Strooper and Alberta Leon
Journal of Pharmacology and Experimental Therapeutics December 2007, 323 (3) 822-830; DOI: https://doi.org/10.1124/jpet.107.129007
Bruno P. Imbimbo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elda Del Giudice
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Davide Colavito
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonello D'Arrigo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maurizio Dalle Carbonare
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gino Villetti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabrizio Facchinetti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberta Volta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vladimiro Pietrini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria F. Baroc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lutgarde Serneels
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bart De Strooper
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberta Leon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Some nonsteroidal anti-inflammatory drugs has been shown to allosterically modulate the activity of γ-secretase, the enzymatic complex responsible for the formation of β-amyloid (Aβ). 1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074) is a new γ-secretase modulator, devoid of anticyclooxygenase (COX) and Notch-interfering activities in vitro. We evaluated the effects of chronic CHF5074 treatment on brain Aβ pathology in Tg2576 transgenic mice. Twenty-eight animals of 9.5 to 10.5 months of age received CHF5074-medicated diet (375 ppm) or standard diet for 17 weeks. Compared with controls, CHF5074 treatment significantly reduced the area occupied by plaques and the number of plaques in cortex (–52.2 ± 5.6%, p = 0.0003 and –48.9 ± 6.6%, p = 0.0004, respectively) and hippocampus (–76.7 ± 6.4%, p = 0.004 and –66.2 ± 10.3%, p = 0.037, respectively). Biochemical analysis confirmed the histopathological measures, with CHF5074-treated animals showing reduced total brain Aβ40 (–49.2 ± 9.2%, p = 0.017) and Aβ42 (–43.5 ± 9.7%, p = 0.027) levels. In a human neuroglioma cell line expressing Swedish mutated form of amyloid precursor protein (H4swe), CHF5074 reduced Aβ42 and Aβ40 secretion, with an IC50 of 3.6 and 18.4 μM, respectively, values consistent with those measured in the brain of the CHF5074-treated Tg2576 mice (6.4 ± 0.4 μM). At 5 μM, no effects were observed on Notch intracellular cleavage in human embryonic kidney 293swe cells. CHF5074 was well tolerated by Tg2576 mice. No abnormal findings were observed upon histopathological examination of the gastrointestinal tract, indicating the absence of COX-related toxicity. Semiquantitative histochemical evaluation of goblet cells in the ileum of vehicle- and CHF5074-treated animals yielded similar results, suggesting no effects on Notch pathway. CHF5074 is therefore a promising therapeutic agent for Alzheimer's disease.

Footnotes

  • The work was sponsored by Chiesi Farmaceutici, Parma, Italy. A part of this study was presented at the 8th International Conference on Alzheimer's and Parkinson's Diseases; 2007 March 14–18; Salzburg, Austria.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.107.129007.

  • ABBREVIATIONS: AD, Alzheimer's disease; Aβ, β-amyloid peptide; APP, amyloid precursor protein; NSAID, nonsteroidal anti-inflammatory drug; COX, cyclooxygenase; CHF5074, 1-(3′,4′-dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic acid; APPswe, Swedish mutated form of APP; H4swe, human neuroglioma cell line expressing APPswe; HEK293swe, human embryonic kidney 293 cells expressing APPswe; FA, formic acid; ELISA, enzyme-linked immunosorbent assay; GFAP, glial fibrillar acidic protein; MRK-560, N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethane sulfonamide.

    • Received July 20, 2007.
    • Accepted September 24, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 387 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 387, Issue 1
1 Oct 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel γ-Secretase Modulator, Reduces Brain β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel γ-Secretase Modulator, Reduces Brain β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity

Bruno P. Imbimbo, Elda Del Giudice, Davide Colavito, Antonello D'Arrigo, Maurizio Dalle Carbonare, Gino Villetti, Fabrizio Facchinetti, Roberta Volta, Vladimiro Pietrini, Maria F. Baroc, Lutgarde Serneels, Bart De Strooper and Alberta Leon
Journal of Pharmacology and Experimental Therapeutics December 1, 2007, 323 (3) 822-830; DOI: https://doi.org/10.1124/jpet.107.129007

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel γ-Secretase Modulator, Reduces Brain β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity

Bruno P. Imbimbo, Elda Del Giudice, Davide Colavito, Antonello D'Arrigo, Maurizio Dalle Carbonare, Gino Villetti, Fabrizio Facchinetti, Roberta Volta, Vladimiro Pietrini, Maria F. Baroc, Lutgarde Serneels, Bart De Strooper and Alberta Leon
Journal of Pharmacology and Experimental Therapeutics December 1, 2007, 323 (3) 822-830; DOI: https://doi.org/10.1124/jpet.107.129007
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Combination therapy against cholinergic-induced SE
  • Sex Differences in Benzodiazepine Refractory Status Epilepticus
  • Biodistribution of Agmatine to Brain and Spinal Cord
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics